Drug combinations are becoming a standard treatment of many complex diseases due to their capability to overcome resistance to monotherapy. In the current preclinical drug combination screening, the t
Viability assays were performed in 4 NSCLC cell lines (H157, H332, H1299 and H2170) with a customized library of 240 targeted agents in combination with palbociclib or abemaciclib. The library drug ch
